Original Publications:

2017

CTLA-4/CD80 pathway regulates T cell infiltration into pancreatic cancer. Bengsch F, Knoblock DM, Liu A, McAllister F, Beatty GL. Cancer Immunol Immunother. 2017 Dec;66(12):1609-1617.

IL6 Receptor Blockade Enhances Chemotherapy Efficacy in Pancreatic Ductal Adenocarcinoma. Long KB, Tooker G, Tooker E, Luque SL, Lee JW, Pan X, Beatty GL. Mol Cancer Ther. 2017 Sep;16(9):1898-1908. doi: 10.1158/1535-7163.

First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies. Beatty GL, O'Dwyer PJ, Clark J, Shi JG, Bowman KJ, Scherle PA, Newton RC, Schaub R, Maleski J, Leopold L, Gajewski TF. Clin Cancer Res. 2017 Jul 1;23(13):3269-3276.

Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma. Kalbasi A, Komar C, Tooker GM, Liu M, Lee JW, Gladney WL, Ben-Josef E, Beatty GL. Clin Cancer Res. 2017 Jan 1;23(1):137-148.

 

2016

IFNγ and CCL2 Cooperate to Redirect Tumor-Infiltrating Monocytes to Degrade Fibrosis and Enhance Chemotherapy Efficacy in Pancreatic Carcinoma. Long KB, Gladney WL, Tooker GM, Graham K, Fraietta JA, Beatty GL. Cancer Discov. 2016 Apr;6(4):400-413.

 

2015

Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages Beatty GL, Winograd R, Evans RA, Long KB, Luque SL, Lee JW, Clendenin C, Gladney WL, Knoblock DM, Guirnalda PD, Vonderheide RH. Gastroenterology. 2015 Jul;149(1):201-10.

 

2014

Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM, Kalos M, June CH. Cancer Immunol Res. 2014 Feb;2(2):112-20.

 

2013

A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Beatty GL, Torigian DA, Chiorean EG, Saboury B, Brothers A, Alavi A, Troxel AB, Sun W, Teitelbaum UR, Vonderheide RH, O'Dwyer PJ. Clin Cancer Res. 2013 Nov 15;19(22):6286-95.

 

2011

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, Torigian DA, O'Dwyer PJ, Vonderheide RH. Science. 2011 Mar 25;331(6024):1612-6.

 

Select Reviews:

2017

Deploying Immunotherapy in Pancreatic Cancer: Defining Mechanisms of Response and Resistance. Beatty GL, Eghbali S, Kim R. Am Soc Clin Oncol Educ Book. 2017;37:267-278.

Functio Laesa: Cancer Inflammation and Therapeutic Resistance. Liu M, Kalbasi A, Beatty GL. J Oncol Pract. 2017 Mar;13(3):173-180.

Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists. Beatty GL, Li Y, Long KB. Expert Rev Anticancer Ther. 2017 Feb;17(2):175-186.

 

2016

Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps. Beatty GL, O'Hara M. Pharmacol Ther. 2016 Oct;166:30-9.

Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (LSL-Kras(G12D/+) ;LSL-Trp53(R172H/+) ;Pdx-1-Cre), Its Variants, and Their Application in Immuno-oncology Drug Discovery. Lee JW, Komar CA, Bengsch F, Graham K, Beatty GL. Curr Protoc Pharmacol. 2016 Jun 1;73:14.39.1-14.39.20.

 

2015

Immune escape mechanisms as a guide for cancer immunotherapy. Beatty GL, Gladney WL. Clin Cancer Res. 2015 Feb 15;21(4):687-92. doi: 10.1158/1078-0432.

 

2013

Harnessing the antitumor potential of macrophages for cancer immunotherapy. Long KB, Beatty GL. Oncoimmunology. 2013 Dec 1;2(12):e26860.